Provided is a immunoglobulin that binds IgE with high affinity. The antibody is capable of inhibiting cells that express membrane-anchored IgE. Also, the antibody is useful for treating IgE-mediated disorders, including allergies and asthma.
Figure 1 Inhibition of IgE binding to FcεRIα through ligelizumab or omalizumab IgG by ELISA.
Inhibition of IgE binding to FcεRIα and CD23 by ligelizumab or omalizumab.
Gasser, P., Tarchevskaya, S. S., Guntern, P., Brigger, D., Ruppli, R., Zbären, N., ... & Eggel, A. (2020). The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nature communications, 11(1), 1-14.
Figure 2 Isolated primary human blood basophils are gated as SSClow, FSClow, CD123+, CD193+ double-positive cells.
After resensitization with recombinant human JW8-IgE (dashed gray line) is shown.
Gasser, P., Tarchevskaya, S. S., Guntern, P., Brigger, D., Ruppli, R., Zbären, N., ... & Eggel, A. (2020). The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nature communications, 11(1), 1-14.
Figure 3 Representative flow cytometry plots and quantification of IgG-positive RPMI8866 cell frequencies.
Representative image stream flow cytometry pictures for IgE staining.
Gasser, P., Tarchevskaya, S. S., Guntern, P., Brigger, D., Ruppli, R., Zbären, N., ... & Eggel, A. (2020). The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nature communications, 11(1), 1-14.
Figure 4 Co-localization analysis for IgE staining of IgE-sensitized RPMI8866 cells.
Binding of CD23:IgE complexes by ligelizumab or omalizumab.
Gasser, P., Tarchevskaya, S. S., Guntern, P., Brigger, D., Ruppli, R., Zbären, N., ... & Eggel, A. (2020). The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nature communications, 11(1), 1-14.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-034ZJ | Anti-Human IgE Recombinant Antibody (CMAB007) | ELISA | Humanized antibody |
TAB-049ZJ | Anti-Human IgE Recombinant Antibody (IGE009) | ELISA, Inhib, FC | Humanized antibody |
TAB-050ZJ | Anti-Human IgE Recombinant Antibody (IGE026) | ELISA, Inhib, FC | Humanized antibody |
TAB-034ZJ-F(E) | Anti-Human IgE Recombinant Antibody Fab Fragment (CMAB007) | ELISA | Humanized antibody |
TAB-049ZJ-F(E) | Anti-Human IgE Recombinant Antibody Fab Fragment (IGE009) | ELISA, Inhib, FC | Humanized antibody |
There are currently no Customer reviews or questions for HPAB-AP674-YC. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.